Catalyst Pharmaceuticals Partners, Inc. (CPRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$31.490.00%
Close 2026-07-16 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CPRX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 597.0 | 589.0 | 491.7 | 398.2 | 214.2 | 140.8 | 119.1 | 0.5 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — |
| Total Revenues | — | — | — | — | — | — | 119.1 | 0.5 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — |
| Cost of Revenues | 83.8 | 87.3 | 68.8 | 52.0 | 34.4 | 21.9 | 17.0 | 14.8 | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 196.2 | 193.8 | 177.7 | 133.7 | 57.1 | 49.6 | 44.2 | 36.9 | — | — | — | — | — | — | — | — |
| R&D Expenses | 11.5 | 12.7 | 12.6 | 93.2 | 19.8 | 16.9 | 16.5 | 18.8 | 19.9 | 11.4 | 11.4 | 11.8 | 10.1 | 8.1 | 2.7 | 3.4 |
| Operating Income | 267.6 | 257.8 | 195.1 | 86.8 | 101.8 | 52.4 | 41.3 | 31.8 | (35.3) | (18.7) | (19.3) | (20.4) | (14.6) | (10.3) | (5.2) | (6.1) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 |
| EBT, Incl. Unusual Items | 296.5 | 283.5 | 216.3 | 94.5 | 104.7 | 52.7 | 41.9 | 33.4 | (34.0) | (18.4) | (18.1) | (20.2) | (15.5) | (12.2) | (4.1) | (6.4) |
| Income Tax Expense | 75.1 | 69.2 | 52.4 | 23.1 | 21.6 | 13.2 | (33.1) | 1.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | 221.3 | 214.3 | 163.9 | 71.4 | 83.1 | 39.5 | 75.0 | 31.9 | (34.0) | (18.4) | (18.1) | (20.2) | (15.5) | (12.2) | (4.1) | (6.4) |
| Per Share | ||||||||||||||||
| Basic EPS | 1.81 | 1.75 | 1.38 | 0.67 | 0.80 | 0.38 | 0.72 | 0.31 | — | — | — | — | — | — | — | — |
| Diluted EPS | 1.74 | 1.68 | 1.31 | 0.63 | 0.75 | 0.37 | 0.71 | 0.30 | — | — | — | — | — | — | — | — |
| Revenue per Share | 4.70 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 122.3 | 122.3 | 118.5 | 106.3 | 103.4 | 103.4 | 103.5 | 102.9 | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 126.9 | 127.3 | 124.9 | 113.8 | 111.4 | 107.8 | 106.2 | 106.0 | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | (10.3) | (5.2) | (6.0) |
| EBIT | 267.6 | 257.8 | 195.1 | 86.8 | 101.8 | 52.4 | 41.3 | 31.8 | (35.3) | (18.7) | (19.3) | (20.4) | (14.6) | (10.3) | (5.2) | (6.1) |
| Effective Tax Rate | 25.3% | — | — | 24.4% | 20.7% | 25.0% | -79.0% | 4.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.